Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC) Market Research Report: (2022-2027)

By Diagnosis (Blood Tests (AFP (Alfa-Fetoprotein), LFT (Liver Function Test)), Hepatic Angiography, Liver Biopsy, Laparoscopy, Others (MRI, CT scan, etc.)), By Treatment (Surgery (Hepatectomy, Liver T Read more

  • Healthcare
  • Jun 2022
  • 198
  • HC22082

Market Definition

Hepatocellular Carcinoma (HCC) is a liver malignancy that emerges in liver cells and is the sixth most common cancer worldwide. It is the third most cause of cancer-related deaths globally, with prominent risk factors, including excessive alcohol consumption, HBV (Hepatitis B Virus) & HCV (Hepatitis C Virus) infections, and other lifestyle disorders.

Market Insights

The Global Hepatocellular Carcinoma (HCC) Market is projected to grow at a CAGR of around 10.20% during the forecast period, i.e., 2022-27. The growth of the market is driven primarily by the increasing instances of liver cancer & rising mortality rates owing to severe lifestyle changes and increasing obesity on account of poor eating habits, coupled with significant investments in research activities associated with the development of advanced therapeutics for HCC.

Report Coverage Details
Study Period Historical Data: 2017-20
Base Year: 2021
Forecast Period: 2022-27
CAGR 10.20%
Regions Covered North America: The US, Canada, Mexico
Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe
Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific
South America: Brazil, Rest of Latin America
Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa
Key Companies Profiled

Amgen Inc., AstraZeneca plc, Bayer AG, BeiGene, Bristol Myers Squibb, Eisai Co., Ltd., Merck & Co., Inc., Novartis International AG, Pfizer Inc.

Unit Denominations USD Million/Billion

 

Moreover, the rapidly surging clinical trials for HCC drugs & medications by the leading biotech & pharma companies are further creating lucrative prospects for the global market through 2027. FDA, PMDA, & EMA, among other regulatory agencies worldwide, are offering significant incentives to biopharma companies for developing orphan drugs for rare diseases while also providing fast drug approvals. For instance:

  • In April 2022, FDA granted Orphan Drug Designation (ODD) to TTI-101, an orally delivered, small molecule, STAT3 inhibitor developed by Tvardi Therapeutics, Inc., for HCC treatment.
  • In February, the US-based agency authorized ODD to two autologous & gene-edited T-cell immunotherapies (ET140203 & ECT204, developed by Eureka Therapeutics) for the treatment of patients with advanced HCC.

With the FDA approval of Avastin (bevacizumab) and Tecentriq (atezolizumab) as the first-line HCC treatment, healthcare R&D has been focusing extensively on developing more effective and affordable combination therapies.

Combinations of PD- 1 or PDL- 1 with multikinase inhibitors, anti-VEGF drugs, or CTLA- 4 inhibitors are already well represented in late-stage HCC. As a result, the rising cases of liver cancer worldwide are creating numerous opportunities for these medications, which, in turn, would expand the global market in the years to come.

However, adverse effects like skin & gastrointestinal disorders, fatigue, hair loss, etc., in many patients suffering from HCC due to high drug dosage, coupled with the unavailability of HCC diagnoses & treatments in rural areas, are a few aspects projected to hinder the growth of the Global Hepatocellular Carcinoma (HCC) Market through 2027.

  1. Introduction
    1. Research Process
    2. Assumption
    3. Market Segmentation
    4. Market Definition
  2. Executive Summary
  3. Global Hepatocellular Carcinoma (HCC) Market Trends & Insights
  4. Global Hepatocellular Carcinoma (HCC) Market Regulation & Policy, By Country
  5. Global Hepatocellular Carcinoma (HCC) Market Dynamics
    1. Growth Drivers
    2. Challenges
    3. Impact Analysis
  6. Global Hepatocellular Carcinoma (HCC) Market Hotspot and Opportunities
  7. Global Hepatocellular Carcinoma (HCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
        1. Blood Tests
          1. AFP (Alfa-Fetoprotein)
          2. LFT (Liver Function Test)
        2. Hepatic Angiography
        3. Liver Biopsy
        4. Laparoscopy
        5. Others (MRI, CT scan, etc.)
      2. By Treatment
        1. Chemotherapy
          1. Cisplatin
          2. Gemcitabine (Gemzar)
          3. Oxaliplatin (Eloxatin)
          4. Doxorubicin (pegylated liposomal doxorubicin)
          5. 5-fluorouracil (5-FU)
        2. Immunotherapy
          1. Atezolizumab (Tecentriq)
          2. Pembrolizumab (Keytruda)
          3. Nivolumab (Opdivo)
          4. Ipilimumab (Yervoy)
        3. Surgery
          1. Hepatectomy
          2. Liver Transplant
        4. Radiation Therapy
        5. Targeted Therapy
          1. Kinase Inhibitors
            1. Sorafenib
            2. Lenvatinib
            3. Regorafenib (Stivarga)
            4. Cabozantinib (Cabometyx)
          2. Monoclonal Antibodies
            1. Bevacizumab (Avastin)
            2. Ramucirumab (Cyramza)
      3. By End-User
        1. Hospitals
        2. Cancer Centers
        3. Others (Ambulatory Surgery Centers, etc.)
      4. By Region
        1. North America
        2. South America
        3. Europe
        4. Middle East & Africa
        5. Asia-Pacific
      5. By Company
        1. Competition Characteristics
        2. Revenue Shares
        3. Competitor Placement in MarkNtel Advisor’s Quadrant
  8. North America Hepatocellular Carcinoma (HCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. The US
        2. Canada
        3. Mexico
  9. South America Hepatocellular Carcinoma (HCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. Brazil
        2. Rest of Latin America
  10. Europe Hepatocellular Carcinoma (HCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. The UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
  11. Middle East & Africa Hepatocellular Carcinoma (HCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. South Africa
        2. GCC
        3. Rest of Middle East & Africa
  12. Asia-Pacific Hepatocellular Carcinoma (HCC) Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Treatment
      3. By End-User
      4. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. South East Asia
        6. Rest of Asia Pacific
  13. Global Hepatocellular Carcinoma (HCC) Market Key Strategic Imperatives for Success and Growth
  14. Competitive Outlook
    1. Competition Matrix
      1. By Application Portfolio
      2. Brand Specialization
      3. Target Markets
      4. Target by Applications
      5. Research & Development
      6. Strategic Alliances
      7. Strategic Initiatives
    2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
      1. Amgen Inc.
      2. AstraZeneca plc
      3. Bayer AG
      4. BeiGene
      5. Bristol Myers Squibb
      6. Eisai Co., Ltd.
      7. Merck & Co., Inc.
      8. Novartis International AG
      9. Pfizer Inc.
  15. Disclaimer
 Hepatocellular Carcinoma (HCC) Market Segmentation
*This field is required